| Literature DB >> 33205380 |
Gianluca Costa1, Laura Bersigotti2,3, Giulia Massa1, Luca Lepre4, Pietro Fransvea5, Alessio Lucarini1, Paolo Mercantini1, Genoveffa Balducci1, Gabriele Sganga5, Antonio Crucitti6.
Abstract
BACKGROUND: Frailty assessment has acquired an increasing importance in recent years and it has been demonstrated that this vulnerable profile predisposes elderly patients to a worse outcome after surgery. Therefore, it becomes paramount to perform an accurate stratification of surgical risk in elderly undergoing emergency surgery. STUDYEntities:
Keywords: Emergency surgery; Frailty; Predictive tool; Procedure-specific morbidity
Mesh:
Year: 2020 PMID: 33205380 PMCID: PMC8302529 DOI: 10.1007/s40520-020-01735-5
Source DB: PubMed Journal: Aging Clin Exp Res ISSN: 1594-0667 Impact factor: 3.636
Fig. 1The study flow-chart according to STROBE statement
Organ/body district as site of surgical intervention in Dv set
| Organ/body district | No. of cases (784) | % |
|---|---|---|
| Biliary tract | 177 | 22.6% |
| Abdominal wall | 129 | 16.4% |
| Large bowel | 128 | 16.3% |
| Midgut miscellany | 85 | 10.7% |
| Small bowel (adhesive obstruction) | 83 | 10.6% |
| Upper GI | 76 | 9.7% |
| Appendix | 37 | 4.7% |
| Other various | 69 | 8.8% |
Variables for calculating Emergency Surgery Frailty Index
| Emergency Surgery Frailty Index (EmSFI) | |||
|---|---|---|---|
| Variable | Absent | Present | |
| Age ≥ 80 years | 0 | 1 | |
| Emergency | 0 | 1 | |
| SIRS | 0 | 1 | |
| Malignancy | 0 | 1 | |
| Absent | Mild | Severe | |
| Chronic cardiopathy | 0 | 1 | 2 |
| Chronic pneumopathy | 0 | 1 | 2 |
| Other comorbidities | 0 | 1 | 2 |
| Altered autonomy | 0 | 1 | 2 |
| Altered mobility | 0 | 1 | 2 |
| Maximum score = 14 points | |||
Fig. 2Linear correlation between EmSFI value and Mortality rate in Dv set
Fig. 3EmSFI ROC Curve of Morbidity (left) and Mortality (right) in Dv set
Hosmer–Lemeshow contingency table for mortality in Dv set
| Mortality = 0 | Mortality = 1 | Total | |||
|---|---|---|---|---|---|
| Observed | Expected | Observed | Expected | ||
| 1 | 119 | 118,417 | 4 | 4,583 | 123 |
| 2 | 139 | 137,739 | 6 | 7,261 | 145 |
| 3 | 141 | 138,085 | 7 | 9,915 | 148 |
| 4 | 93 | 96,556 | 13 | 9,444 | 106 |
| 5 | 73 | 78,538 | 16 | 10,462 | 89 |
| 6 | 58 | 57,557 | 10 | 10,443 | 68 |
| 7 | 81 | 77,109 | 24 | 27,891 | 105 |
Hosmer–Lemeshow contingency table for morbidity in Dv set
| Morbidity = 0 | Morbidity = 1 | Total | |||
|---|---|---|---|---|---|
| Observed | Expected | Observed | Expected | ||
| 1 | 100 | 95,769 | 23 | 27,231 | 123 |
| 2 | 112 | 107,825 | 33 | 37,175 | 145 |
| 3 | 99 | 104,369 | 49 | 43,631 | 148 |
| 4 | 69 | 70,343 | 37 | 35,657 | 106 |
| 5 | 50 | 55,121 | 39 | 33,879 | 89 |
| 6 | 39 | 38,962 | 29 | 29,038 | 68 |
| 7 | 53 | 49,611 | 52 | 55,389 | 105 |
Mortality and morbidity rate in development set
| EmSFI risk class | Mortality Dv group | Morbidity Dv group | Clavien II–IV Dv group |
|---|---|---|---|
| EmSFI 1–3 | 17/416 (4.1%) | 105/416 (25.2%) | 80/416 (19.2%) |
| EmSFI 4–7 | 45/312 (14.4%) | 128/312 (41.0%) | 87/312 (27.9%) |
| EmSFI 8–14 | 17/56 (30.4%) | 29/56 (51.8%) | 23/56 (41.1%) |
| Total | 79/784 (10.1%) | 262/784 (33.4%) | 190/784 (24.2%) |
Fig. 4EmSFI ROC Curve of Morbidity (left) and Mortality (right) in Vd set
Mortality and morbidity rate in validation set
| EmSFI risk class | Mortality Vd group | Morbidity Vd group | Clavien II–IV Vd group | Clavien III–IV Vd group |
|---|---|---|---|---|
| EmSFI 1–3 | 2/108 (1.9%) | 42/108 (38.9%) | 34/108 (31.5%) | 20/108 (18.5%) |
| EmSFI 4–7 | 19/110 (17.3%) | 49/110 (44.5%) | 35/110 (31.8%) | 28/110 (25.6%) |
| EmSFI 8–14 | 8/22 (36.4%) | 10/22 (45.5%) | 8/22 (36.4%) | 8/22 (36.4%) |
| Total | 29/240 (12.1%) | 101/240 (42.1%) | 77/240 (32.1%) | 58/240 (24.1%) |